雅仕維(01993.HK)飆43%曾見9.7元上市新高 引資螞蟻金服兼研分拆業務
雅仕維(01993.HK)引資螞蟻金服兼研分拆業務,該股今天逆市飆升曾突破2015年4月所創上市高位7.9元,最多飆升逾1倍至9.7元,現造6.7元,急漲42.6%,街貨少及一向稀疏成交急增至53萬股,為一年來最多,涉資379萬元。
雅仕維公布,以每股4.1元(較昨天收市價折讓約12.8%),向獨立第三方螞蟻金服配售3,567.56萬股新股或佔擴大後股本7.5%,所得淨額1.43億元,擬用作旗下中國和新加坡項目及一般營運資金。同時,公司現正考慮可能將在東南亞、香港和澳門的業務分拆及於一間認可證券交易所獨立上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.